Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Protein Expression of PTTG-1, OCT-4, and KLF-4 in Seminoma: A Pilot Study.

Grande G, Milardi D, Martini M, Cenci T, Gulino G, Mancini F, Bianchi A, Pontecorvi A, Pierconti F.

Front Endocrinol (Lausanne). 2019 Sep 11;10:619. doi: 10.3389/fendo.2019.00619. eCollection 2019.

2.

Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents.

Ricci R, Martini M, Ravegnini G, Cenci T, Milione M, Lanza P, Pierconti F, Santini D, Angelini S, Biondi A, Rosa F, Alfieri S, Clemente G, Persiani R, Cassano A, Pantaleo MA, Larocca LM.

Clin Epigenetics. 2019 Jan 7;11(1):2. doi: 10.1186/s13148-018-0594-9.

3.

Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report.

D'Alessandris QG, Montano N, Martini M, Cenci T, Lauretti L, Stumpo V, Pignotti F, Olivi A, Fernandez E, Larocca LM, Pallini R.

Acta Neurochir (Wien). 2018 Dec;160(12):2387-2391. doi: 10.1007/s00701-018-3697-3. Epub 2018 Oct 11.

PMID:
30306271
4.

Morphology combined with ancillary techniques: An algorithm approach for thyroid nodules.

Rossi ED, Martini M, Capodimonti S, Cenci T, Bilotta M, Pierconti F, Pontecorvi A, Lombardi CP, Fadda G, Larocca LM.

Cytopathology. 2018 Oct;29(5):418-427. doi: 10.1111/cyt.12555. Epub 2018 May 30.

PMID:
29683529
5.

To Obtain More With Less: Cytologic Samples With Ancillary Molecular Techniques-The Useful Role of Liquid-Based Cytology.

Martini M, Capodimonti S, Cenci T, Bilotta M, Fadda G, Larocca LM, Rossi ED.

Arch Pathol Lab Med. 2018 Mar;142(3):299-307. doi: 10.5858/arpa.2017-0148-RA. Review.

PMID:
29494225
6.

Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology?

De Stefano A, Rosanova M, Malapelle U, Martini M, De Falco S, Attademo L, Fiore G, Cenci T, Bellevicine C, De Placido S, Troncone G, Carlomagno C.

Int J Biol Markers. 2017 Oct 31;32(4):e474-e477. doi: 10.5301/ijbm.5000273.

PMID:
28665451
7.

The role of thyroid FNA cytology in pediatric malignant lesions: An overview of the literature.

Rossi ED, Martini M, Cenci T, Capodimonti S, Larocca LM.

Cancer Cytopathol. 2017 Aug;125(8):594-603. doi: 10.1002/cncy.21884. Epub 2017 Jun 5. Review.

8.

A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.

Calegari MA, Inno A, Monterisi S, Orlandi A, Santini D, Basso M, Cassano A, Martini M, Cenci T, de Pascalis I, Camarda F, Barbaro B, Larocca LM, Gori S, Tonini G, Barone C.

Br J Cancer. 2017 May 9;116(10):1279-1286. doi: 10.1038/bjc.2017.109. Epub 2017 Apr 20.

9.

The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.

D'Alessandris QG, Biffoni M, Martini M, Runci D, Buccarelli M, Cenci T, Signore M, Stancato L, Olivi A, De Maria R, Larocca LM, Ricci-Vitiani L, Pallini R.

Neuro Oncol. 2017 Aug 1;19(8):1097-1108. doi: 10.1093/neuonc/now304.

10.

SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.

Pierconti F, Martini M, Cenci T, Petrone GL, Ricci R, Sacco E, Bassi PF, Larocca LM.

Prostate. 2017 May;77(6):597-603. doi: 10.1002/pros.23299. Epub 2017 Feb 1.

PMID:
28144985
11.

The role of miRNAs in the evaluation of follicular thyroid neoplasms: an overview of literature.

Rossi ED, Martini M, Capodimonti S, Cenci T, Larocca LM.

J Am Soc Cytopathol. 2017 May - Jun;6(3):96-104. doi: 10.1016/j.jasc.2017.02.001. Epub 2017 Feb 14. Review.

PMID:
31043264
12.

The Immunohistochemical Analysis of SOCS3 Protein Identifies a Subgroup of Prostatic Cancer Biopsies With Aggressive Behavior.

Pierconti F, Martini M, Cenci T, Larocca LM.

Appl Immunohistochem Mol Morphol. 2018 May/Jun;26(5):324-329. doi: 10.1097/PAI.0000000000000438.

PMID:
27801727
13.

Fractographical Analysis and Biomechanical Considerations of a Tooth Restored With Intracanal Fiber Post: Report of the Fracture and Importance of the Fiber Arrangements.

Wandscher VF, Bergoli CD, Limberger IF, Cenci TP, Baldissara P, Valandro LF.

Oper Dent. 2016 Sep-Oct;41(5):E149-E158.

PMID:
27689841
14.

Divergent gastrointestinal stromal tumors in syndromic settings.

Ricci R, Martini M, Cenci T, Riccioni ME, Maria G, Cassano A, Larocca LM.

Cancer Genet. 2016 Jul-Aug;209(7-8):354-8. doi: 10.1016/j.cancergen.2016.05.073. Epub 2016 May 27.

PMID:
27318444
15.

Morphological features that can predict BRAFV600E -mutated carcinoma in paediatric thyroid cytology.

Rossi ED, Bizzarro T, Martini M, Capodimonti S, Cenci T, Fadda G, Schmitt F, Larocca LM.

Cytopathology. 2017 Feb;28(1):55-64. doi: 10.1111/cyt.12350. Epub 2016 Jun 3.

PMID:
27256275
16.

The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms.

Rossi ED, Bizzarro T, Martini M, Capodimonti S, Sarti D, Cenci T, Bilotta M, Fadda G, Larocca LM.

Endocrine. 2016 Dec;54(3):723-732. doi: 10.1007/s12020-016-0866-0. Epub 2016 Jan 27.

PMID:
26818914
17.

KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study.

Dadduzio V, Basso M, Rossi S, Cenci T, Capodimonti S, Strippoli A, Orlandi A, Cerchiaro E, Schinzari G, Cassano A, Martini M, Barone C.

Mol Diagn Ther. 2016 Feb;20(1):65-74. doi: 10.1007/s40291-015-0178-8.

PMID:
26610798
18.

Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.

Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM.

Cancer Cytopathol. 2015 Oct;123(10):593-602. doi: 10.1002/cncy.21586. Epub 2015 Jul 31.

19.

Circulating hematopoietic stem cells and putative intestinal stem cells in coeliac disease.

Piscaglia AC, Rutella S, Laterza L, Cesario V, Campanale M, Cazzato IA, Ianiro G, Barbaro F, Di Maurizio L, Bonanno G, Cenci T, Cammarota G, Larocca LM, Gasbarrini A.

J Transl Med. 2015 Jul 11;13:220. doi: 10.1186/s12967-015-0591-0.

20.

PDGFRA-mutant syndrome.

Ricci R, Martini M, Cenci T, Carbone A, Lanza P, Biondi A, Rindi G, Cassano A, Larghi A, Persiani R, Larocca LM.

Mod Pathol. 2015 Jul;28(7):954-64. doi: 10.1038/modpathol.2015.56. Epub 2015 May 15.

21.

VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma.

D'Alessandris QG, Martini M, Cenci T, Capo G, Ricci-Vitiani L, Larocca LM, Pallini R.

Neurology. 2015 May 5;84(18):1906-8. doi: 10.1212/WNL.0000000000001543. Epub 2015 Apr 10. No abstract available.

PMID:
25862796
22.

Case of Rectal GI Stromal Tumor Demonstrating that KIT and PDGFRA Mutations Are Not Always Mutually Exclusive.

Ricci R, Martini M, Cenci T, Antinori A, Cassano A, Larocca LM.

J Clin Oncol. 2016 Apr 20;34(12):e107-9. doi: 10.1200/JCO.2013.49.1258. Epub 2014 Jul 14. No abstract available.

PMID:
25024074
23.

Pituitary-tumour-transforming-gene 1 expression in testicular cancer.

Pierconti F, Milardi D, Martini M, Grande G, Cenci T, Gulino G, Larocca LM, Rindi G, Pontecorvi A, De Marinis L.

Andrologia. 2015 May;47(4):427-32. doi: 10.1111/and.12283. Epub 2014 Apr 22.

PMID:
24754453
24.

Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: a cytohistologic institutional experience.

Rossi ED, Martini M, Capodimonti S, Cenci T, Straccia P, Angrisani B, Ricci C, Lanza P, Lombardi CP, Pontecorvi A, Larocca LM, Fadda G.

Cancer Cytopathol. 2014 Jul;122(7):527-35. doi: 10.1002/cncy.21416. Epub 2014 Mar 17.

25.

Dietary exposure to trace elements and radionuclides: the methodology of the Italian Total Diet Study 2012-2014.

D'Amato M, Turrini A, Aureli F, Moracci G, Raggi A, Chiaravalle E, Mangiacotti M, Cenci T, Orletti R, Candela L, di Sandro A, Cubadda F.

Ann Ist Super Sanita. 2013;49(3):272-80. doi: 10.4415/ANN_13_03_07.

26.

Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin.

Ricci-Vitiani L, Runci D, D'Alessandris QG, Cenci T, Martini M, Bianchi F, Maira G, Stancato L, De Maria R, Larocca LM, Pallini R.

Neoplasia. 2013 Jul;15(7):773-82.

27.

Evaluation of the quality of foods for special diets produced in a school catering facility within a HACCP-based approach: a case study.

Petruzzelli A, Foglini M, Paolini F, Framboas M, Serena Altissimi M, Naceur Haouet M, Mangili P, Osimani A, Clementi F, Cenci T, Tonucci F.

Int J Environ Health Res. 2014;24(1):73-81. doi: 10.1080/09603123.2013.782605. Epub 2013 Apr 2.

PMID:
23544419
28.

Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma.

Rossi ED, Martini M, Capodimonti S, Straccia P, Cenci T, Lombardi CP, Pontecorvi A, Larocca LM, Fadda G.

Eur J Endocrinol. 2013 May 2;168(6):853-9. doi: 10.1530/EJE-13-0023. Print 2013 Jun.

PMID:
23513230
29.

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients.

Basso M, Strippoli A, Orlandi A, Martini M, Calegari MA, Schinzari G, Di Salvatore M, Cenci T, Cassano A, Larocca LM, Barone C.

Br J Cancer. 2013 Jan 15;108(1):115-20. doi: 10.1038/bjc.2012.526. Epub 2012 Nov 22.

30.

Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis.

Martini M, Cenci T, D'Alessandris GQ, Cesarini V, Cocomazzi A, Ricci-Vitiani L, De Maria R, Pallini R, Larocca LM.

Cancer. 2013 Mar 1;119(5):1004-12. doi: 10.1002/cncr.27821. Epub 2012 Nov 6.

31.

Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.

D'Alessandris QG, Montano N, Cenci T, Martini M, Lauretti L, Bianchi F, Larocca LM, Maira G, Fernandez E, Pallini R.

Acta Neurochir (Wien). 2013 Jan;155(1):33-40. doi: 10.1007/s00701-012-1536-5. Epub 2012 Nov 8.

PMID:
23132371
32.

Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma.

Cenci T, Martini M, Montano N, D'Alessandris QG, Falchetti ML, Annibali D, Savino M, Bianchi F, Pierconti F, Nasi S, Pallini R, Larocca LM.

Am J Clin Pathol. 2012 Sep;138(3):390-6. doi: 10.1309/AJCPRXHNJQLO09QA.

PMID:
22912356
33.

Von hippel-lindau disease and erythrocytosis.

Capodimonti S, Teofili L, Martini M, Cenci T, Iachininoto MG, Nuzzolo ER, Bianchi M, Murdolo M, Leone G, Larocca LM.

J Clin Oncol. 2012 May 1;30(13):e137-9. doi: 10.1200/JCO.2011.38.6797. Epub 2012 Mar 5. No abstract available.

PMID:
22393103
34.

Expression of EGFRvIII in glioblastoma: prognostic significance revisited.

Montano N, Cenci T, Martini M, D'Alessandris QG, Pelacchi F, Ricci-Vitiani L, Maira G, De Maria R, Larocca LM, Pallini R.

Neoplasia. 2011 Dec;13(12):1113-21.

35.

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C.

Clin Colorectal Cancer. 2011 Dec;10(4):325-32. doi: 10.1016/j.clcc.2011.03.028. Epub 2011 May 11.

PMID:
21729677
36.

The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma.

Hohaus S, Santangelo R, Giachelia M, Vannata B, Massini G, Cuccaro A, Martini M, Cesarini V, Cenci T, D'Alo F, Voso MT, Fadda G, Leone G, Larocca LM.

Clin Cancer Res. 2011 May 1;17(9):2885-92. doi: 10.1158/1078-0432.CCR-10-3327. Epub 2011 Apr 8.

37.

Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms.

Teofili L, Martini M, Iachininoto MG, Capodimonti S, Nuzzolo ER, Torti L, Cenci T, Larocca LM, Leone G.

Blood. 2011 Mar 3;117(9):2700-7. doi: 10.1182/blood-2010-07-297598. Epub 2011 Jan 6.

PMID:
21212285
38.

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.

Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, De Maria R.

Nature. 2010 Dec 9;468(7325):824-8. doi: 10.1038/nature09557. Epub 2010 Nov 21. Erratum in: Nature. 2011 Jan 20;469(7330):432. Nature. 2011 Sep 8;477(7363):238.

PMID:
21102434
39.

Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.

Pallini R, Ricci-Vitiani L, Montano N, Mollinari C, Biffoni M, Cenci T, Pierconti F, Martini M, De Maria R, Larocca LM.

Cancer. 2011 Jan 1;117(1):162-74. doi: 10.1002/cncr.25581. Epub 2010 Aug 30. Erratum in: Cancer. 2016 Oct;122(19):3090.

40.

Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior.

Pierconti F, Martini M, Pinto F, Cenci T, Capodimonti S, Calarco A, Bassi PF, Larocca LM.

Prostate. 2011 Feb 15;71(3):318-25. doi: 10.1002/pros.21245. Epub 2010 Aug 17.

PMID:
20717995
41.

Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosis.

Teofili L, Giona F, Martini M, Torti L, Cenci T, Foà R, Leone G, Larocca LM.

J Clin Oncol. 2010 Jul 1;28(19):e317-8. doi: 10.1200/JCO.2010.29.0387. Epub 2010 Jun 1. No abstract available.

PMID:
20516451
42.

Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis.

Teofili L, Giona F, Torti L, Cenci T, Ricerca BM, Rumi C, Nunes V, Foà R, Leone G, Martini M, Larocca LM.

Haematologica. 2010 Jan;95(1):65-70. doi: 10.3324/haematol.2009.007542. Epub 2009 Aug 27.

43.

The mutant JAK2 allele burden in children with essential thrombocythemia.

Teofili L, Cenci T, Martini M, Capodimonti S, Torti L, Giona F, Amendola A, Randi ML, Putti MC, Scapin M, Leone G, Larocca LM.

Br J Haematol. 2009 May;145(3):430-2. doi: 10.1111/j.1365-2141.2009.07591.x. Epub 2009 Feb 4. No abstract available.

PMID:
19208099
44.

Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme.

Martini M, Pallini R, Luongo G, Cenci T, Lucantoni C, Larocca LM.

Int J Cancer. 2008 Dec 15;123(12):2955-60. doi: 10.1002/ijc.23805.

45.

Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases.

Teofili L, Martini M, Cenci T, Guidi F, Torti L, Giona F, Foà R, Leone G, Larocca LM.

Int J Cancer. 2008 Oct 1;123(7):1586-92. doi: 10.1002/ijc.23694.

46.

A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis.

Martini M, Teofili L, Cenci T, Giona F, Torti L, Rea M, Foà R, Leone G, Larocca LM.

Haematologica. 2008 Jul;93(7):1068-71. doi: 10.3324/haematol.13210. Epub 2008 May 27.

47.

Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma.

Martini M, Hohaus S, Petrucci G, Cenci T, Pierconti F, Massini G, Teofili L, Leone G, Larocca LM.

Am J Clin Pathol. 2008 Mar;129(3):472-7. doi: 10.1309/63H1A83HRTBQ07DB.

PMID:
18285272
48.

The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Leone G, Foà R, Larocca LM.

Blood. 2007 Nov 1;110(9):3384-6. Epub 2007 Jul 20.

PMID:
17644735
49.

Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation.

Teofili L, Martini M, Cenci T, Petrucci G, Torti L, Storti S, Guidi F, Leone G, Larocca LM.

Blood. 2007 Jul 1;110(1):354-9. Epub 2007 Mar 21.

PMID:
17376889
50.

Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.

J Clin Oncol. 2007 Mar 20;25(9):1048-53.

PMID:
17369568

Supplemental Content

Support Center